Cargando…

Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters

PURPOSE: This prospective study aimed to evaluate the difference between (99m)Tc-PSMA single-photon emission computed tomography (SPECT)/CT and multiparametric magnetic resonance imaging (mpMRI) in the detection of primary prostate cancer (PCa). MATERIALS AND METHODS: Fifty-six men with suspected PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Shi, Yuanying, Ye, Liefu, Li, Tao, Wei, Yongbao, Lin, Zhiyi, Chen, Wenxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520245/
https://www.ncbi.nlm.nih.gov/pubmed/37766869
http://dx.doi.org/10.3389/fonc.2023.1193370
_version_ 1785109875181748224
author Zhang, Yu
Shi, Yuanying
Ye, Liefu
Li, Tao
Wei, Yongbao
Lin, Zhiyi
Chen, Wenxin
author_facet Zhang, Yu
Shi, Yuanying
Ye, Liefu
Li, Tao
Wei, Yongbao
Lin, Zhiyi
Chen, Wenxin
author_sort Zhang, Yu
collection PubMed
description PURPOSE: This prospective study aimed to evaluate the difference between (99m)Tc-PSMA single-photon emission computed tomography (SPECT)/CT and multiparametric magnetic resonance imaging (mpMRI) in the detection of primary prostate cancer (PCa). MATERIALS AND METHODS: Fifty-six men with suspected PCa between October 2019 and November 2022 were prospectively enrolled in this study. The median age of the patients was 70 years (range, 29-87 years). Patients were divided into high-(Gleason score>7, n=31), medium- (Gleason score=7, n=6) and low-risk groups (Gleason score < 7, n=6). All patients underwent (99m)Tc-PSMA SPECT/CT and mpMRI at an average interval of 3 days (range, 1-7 days). The maximum standardized uptake value (SUV(max)), the minimum apparent diffusion coefficient (ADC(min)), and their ratio (SUV(max)/ADC(min)) were used as imaging parameters to distinguish benign from malignant prostatic lesions. RESULTS: Of the 56 patients, 12 were pathologically diagnosed with a benign disease, and 44 were diagnosed with PCa. (99m)Tc-PSMA SPECT/CT and mpMRI showed no significant difference in the detection of primary PCa (kappa =0.401, P=0.002), with sensitivities of 97.7% (43/44) and 90.9% (40/44), specificities of 75.0% (9/12) and 75.0% (9/12), and AUC of 97.4% and 95.1%, respectively. The AUC of SUV(max)/ADC(min) was better than those of SUV(max) or ADC(min) alone. When SUV(max)/ADC(min) in the prostatic lesion was >7.0×10(3), the lesion was more likely to be malignant. When SUV(max)/ADC(min) in the prostatic lesion is >27.0×10(3), the PCa patient may have lymph node and bone metastases. SUV(max) was positively correlated with the Gleason score (r=0.61, P=0.008), whereas ADC(min) was negatively correlated with the Gleason score (r=-0.35, P=0.023). SUV(max)/ADC(min) was positively correlated with the Gleason score (r=0.59, P=0.023). SUV(max)/ADC(min) was the main predictor of the high-risk group, with an optimal cut-off value of 15.0×10(3). CONCLUSIONS: The combination of (99m)Tc-PSMA SPECT/CT and mpMRI can improve the diagnostic efficacy for PCa compared with either modality alone; SUV(max)/ADC(min) is a valuable differential diagnostic imaging parameter.
format Online
Article
Text
id pubmed-10520245
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105202452023-09-27 Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters Zhang, Yu Shi, Yuanying Ye, Liefu Li, Tao Wei, Yongbao Lin, Zhiyi Chen, Wenxin Front Oncol Oncology PURPOSE: This prospective study aimed to evaluate the difference between (99m)Tc-PSMA single-photon emission computed tomography (SPECT)/CT and multiparametric magnetic resonance imaging (mpMRI) in the detection of primary prostate cancer (PCa). MATERIALS AND METHODS: Fifty-six men with suspected PCa between October 2019 and November 2022 were prospectively enrolled in this study. The median age of the patients was 70 years (range, 29-87 years). Patients were divided into high-(Gleason score>7, n=31), medium- (Gleason score=7, n=6) and low-risk groups (Gleason score < 7, n=6). All patients underwent (99m)Tc-PSMA SPECT/CT and mpMRI at an average interval of 3 days (range, 1-7 days). The maximum standardized uptake value (SUV(max)), the minimum apparent diffusion coefficient (ADC(min)), and their ratio (SUV(max)/ADC(min)) were used as imaging parameters to distinguish benign from malignant prostatic lesions. RESULTS: Of the 56 patients, 12 were pathologically diagnosed with a benign disease, and 44 were diagnosed with PCa. (99m)Tc-PSMA SPECT/CT and mpMRI showed no significant difference in the detection of primary PCa (kappa =0.401, P=0.002), with sensitivities of 97.7% (43/44) and 90.9% (40/44), specificities of 75.0% (9/12) and 75.0% (9/12), and AUC of 97.4% and 95.1%, respectively. The AUC of SUV(max)/ADC(min) was better than those of SUV(max) or ADC(min) alone. When SUV(max)/ADC(min) in the prostatic lesion was >7.0×10(3), the lesion was more likely to be malignant. When SUV(max)/ADC(min) in the prostatic lesion is >27.0×10(3), the PCa patient may have lymph node and bone metastases. SUV(max) was positively correlated with the Gleason score (r=0.61, P=0.008), whereas ADC(min) was negatively correlated with the Gleason score (r=-0.35, P=0.023). SUV(max)/ADC(min) was positively correlated with the Gleason score (r=0.59, P=0.023). SUV(max)/ADC(min) was the main predictor of the high-risk group, with an optimal cut-off value of 15.0×10(3). CONCLUSIONS: The combination of (99m)Tc-PSMA SPECT/CT and mpMRI can improve the diagnostic efficacy for PCa compared with either modality alone; SUV(max)/ADC(min) is a valuable differential diagnostic imaging parameter. Frontiers Media S.A. 2023-09-11 /pmc/articles/PMC10520245/ /pubmed/37766869 http://dx.doi.org/10.3389/fonc.2023.1193370 Text en Copyright © 2023 Zhang, Shi, Ye, Li, Wei, Lin and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Yu
Shi, Yuanying
Ye, Liefu
Li, Tao
Wei, Yongbao
Lin, Zhiyi
Chen, Wenxin
Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters
title Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters
title_full Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters
title_fullStr Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters
title_full_unstemmed Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters
title_short Improving diagnostic efficacy of primary prostate cancer with combined (99m)Tc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters
title_sort improving diagnostic efficacy of primary prostate cancer with combined (99m)tc-psma spect/ct and multiparametric-mri and quantitative parameters
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520245/
https://www.ncbi.nlm.nih.gov/pubmed/37766869
http://dx.doi.org/10.3389/fonc.2023.1193370
work_keys_str_mv AT zhangyu improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters
AT shiyuanying improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters
AT yeliefu improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters
AT litao improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters
AT weiyongbao improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters
AT linzhiyi improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters
AT chenwenxin improvingdiagnosticefficacyofprimaryprostatecancerwithcombined99mtcpsmaspectctandmultiparametricmriandquantitativeparameters